Phleboliths in varicoceles presenting as spermatic cord massStephen Lazarou
Harvard Medical School, Division of Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Fertil Steril 86:219.e21-2. 2006
..To discuss the diagnosis and management of phleboliths in the dilated veins of a varicocele...
- Testosterone therapy for men at risk for or with history of prostate cancer
Abraham Morgentaler
Men s Health Boston Harvard Medical School, One Brookline Place, Suite 624, Brookline, MA 02445, USA
Curr Treat Options Oncol 7:363-9. 2006
..Although still controversial, there appears to be little reason to withhold TRT from men with favorable outcomes after definitive treatment for PCa. Monitoring with PSA and digital rectal examination at regular intervals is recommended...
Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical studyAbraham Morgentaler
Men s Health Boston, Brookline, Massachusetts 02445, USA
J Urol 180:2307-13. 2008
..We determined the pharmacokinetics and safety of 750 mg long acting testosterone undecanoate given intramuscularly at 0, 4 and 14 weeks to men with hypogonadism...
- Testosterone deficiency and Peyronie's disease: pilot data suggesting a significant relationship
Sergio A Moreno
Harvard Medical School, Boston, MA, USA
J Sex Med 6:1729-35. 2009
..As testosterone (T) has been shown to influence wound healing, and serum T declines in the age group at risk for Peyronie's disease (PD), we explored the possibility that low serum T may be associated with PD...
- Is testosterone a friend or a foe of the prostate?
Emmanuele A Jannini
Department of Experimental Medicine, University of L Aquila, L Aquila, Italy Men s Health Boston, Harvard Medical School, Boston, MA, USA
J Sex Med 8:946-55. 2011
..Furthermore, currently adequately powered and optimally designed long-term prostate disease data are not available to determine if there is an additional risk from normal T values in cured patients for PCa...
- Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer
Abraham Morgentaler
Harvard Medical School, Urology, Brookline, MA, USA
J Sex Med 6:574-7. 2009
..However, the traditional view regarding the relationship of T to PCa has come under new scrutiny, with recent reports suggesting that PCa growth may not be greatly affected by variations in serum T within the near-physiologic range...
- Guilt by association: a historical perspective on Huggins, testosterone therapy, and prostate cancer
Abraham Morgentaler
Men s Health Boston, Harvard Medical School, Boston, MA 02445, USA
J Sex Med 5:1834-40. 2008
..A long-standing belief is that higher testosterone (T) will increase the risk of prostate cancer (PCa), yet recent studies do not support this view...
- A 66-year-old man with sexual dysfunction
Abraham Morgentaler
Men's Health Boston, Mass 02445, USA
JAMA 291:2994-3003. 2004
- Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth
Abraham Morgentaler
Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Eur Urol 55:310-20. 2009
..The traditional belief that prostate cancer (PCa) growth is dependent on serum testosterone (T) level has been challenged by recent negative studies in noncastrated men...
- Testosterone deficiency
Abdulmaged M Traish
Department of Biochemistry, Division of Urology, Boston University School of Medicine, Mass, USA
Am J Med 124:578-87. 2011
..This review examines a host of studies, with practical recommendations for diagnosis of TD and T repletion in middle-aged and older men, including an analysis of treatment modalities and areas of concerns and uncertainty...
- Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less
Abraham Morgentaler
Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Urology 68:1263-7. 2006
..To determine the prevalence of prostate cancer in hypogonadal men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or less...
- Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone
Luis Reyes Vallejo
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
J Sex Med 4:1757-62. 2007
..Testosterone replacement therapy (TRT) has been shown to be beneficial for men with hypogonadism. However, it is unknown how well hypogonadal men respond to TRT based on the severity of testosterone deficiency...
- Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia
Ernani Luis Rhoden
Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
J Urol 170:2348-51. 2003
..CONCLUSIONS: After 1 year of TRT men with PIN do not have a greater increase in PSA or a significantly increased risk of cancer than men without PIN. These results indicate that TRT is not contraindicated in men with a history of PIN...
- Estrogens in men: clinical implications for sexual function and the treatment of testosterone deficiency
Ravi Kacker
Beth Israel Deaconess Medical Center, Harvard Medical School, Urology, Boston, MA 02116, USA
J Sex Med 9:1681-96. 2012
..The role of estrogens in male sexual function and the pathogenesis of testosterone deficiency remain controversial and poorly understood...
- Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice
Ernani Luis Rhoden
Men s Health Boston, Division of Urology, Harvard Medical School, Boston, MA, USA
J Sex Med 7:277-83. 2010
....
- Erectile dysfunction
Ernani Luis Rhoden
Harvard Medical School, Boston, MA, USA
J Long Term Eff Med Implants 13:519-28. 2003
..This review addresses the etiology, epidemiology, diagnosis, and treatment of erectile dysfunction in light of the remarkable advances in the field...
- Risks of testosterone-replacement therapy and recommendations for monitoring
Ernani Luis Rhoden
Division of Urology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, USA
N Engl J Med 350:482-92. 2004
- Wide variability in laboratory reference values for serum testosterone
Stephen Lazarou
Harvard Medical School, Division of Urology, Beth Israel Deaconess Medical Center, Boston, MA, USA
J Sex Med 3:1085-9. 2006
..CONCLUSIONS. Laboratory reference values for testosterone vary widely, and are established without clinical considerations...
- Testosterone replacement therapy and prostate cancer
Abraham Morgentaler
Men s Health Boston, Brookline, MA, USA
Urol Clin North Am 34:555-63, vii. 2007
..A saturation model is proposed that is consistent with regression of cancer when T is reduced to castrate levels and with lack of observed growth when serum T is increased...
- Technical advances in penile prostheses
Stephen Lazarou
Harvard Medical School, Beth Israel Deaconess Medical Center, Division of Urology, Boston, MA, USA
J Long Term Eff Med Implants 16:235-47. 2006
..These advances make the penile prosthesis an excellent option for the treatment of ED, particularly for men who fail oral therapy...
- Testosterone and prostate cancer: what are the risks for middle-aged men?
Abraham Morgentaler
Men s Health Boston, One Brookline Place, Suite 624, Brookline, MA 02445, USA
Urol Clin North Am 38:119-24. 2011
..This apparent paradox is explained by the Saturation Model, which posits a finite capacity of androgen to stimulate PCa growth. Modern studies indicate no increased risk of PCa among men with serum T in the therapeutic range...
- Comparison of free testosterone results by analog radioimmunoassay and calculated free testosterone in an ambulatory clinical population
Sergio A Moreno
Men s Health Boston, Harvard Medical School, Boston, MA, USA
J Sex Med 7:1948-53. 2010
..Calculated FT (cFT), derived from total testosterone (TT) and sex-hormone binding globulin (SHBG) values has been recommended in its place. There are limited data comparing aFT and cFT in clinical populations...
- Testosterone therapy in men with untreated prostate cancer
Abraham Morgentaler
Men s Health Boston, Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
J Urol 185:1256-60. 2011
..Recent evidence has called this paradigm into question. In this study we investigate the effect of testosterone therapy in men with untreated prostate cancer...
- Hypogonadism in the man with erectile dysfunction: what to look for and when to treat
Stephen Lazarou
Men's Health Boston, One Brookline Place #624, Brookline, MA 02445, USA
Curr Urol Rep 6:476-81. 2005
..Hematocrit or hemoglobin also should be obtained regularly due to the risk of erythrocytosis. Awareness of the benefits of TRT in the man with ED may improve clinical outcomes...
- Testosterone therapy in men with prostate cancer: scientific and ethical considerations
Abraham Morgentaler
Men s Health Boston and the Department of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
J Urol 189:S26-33. 2013
..Pertinent literature regarding the potential use of testosterone therapy in men with prostate cancer is reviewed and synthesized...
- Outcomes with the "V" implantation technique vs. standard technique for testosterone pellet therapy
William Conners
Men s Health Boston, Beth Israel Deaconess Medical Center Harvard University Medical School, Division of Urology, Boston, MA 02445, USA
J Sex Med 8:3465-70. 2011
..While this allows additional pellets to be inserted more easily, and increased space to place those pellets further from the skin incision, it minimally increases the surgical procedure...
- Testosterone replacement therapy and prostate risks: where's the beef?
Abraham Morgentaler
Division of Urology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Can J Urol 13:40-3. 2006
..These results argue against an increased risk of prostate cancer with testosterone replacement therapy...
- Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: Use of a novel noninferiority study design
Abraham Morgentaler
Harvard Medical School, Brookline, MA, USA
J Sex Med 3:492-503. 2006
..CONCLUSION: Tadalafil 20 mg was as efficacious in the Hispanic and black American groups as in the Caucasian/Reference group. Tadalafil was efficacious and well tolerated in each of the groups studied in this trial...
- Testosterone therapy in men with prostate cancer: scientific and ethical considerations
Abraham Morgentaler
Men s Health Boston and the Department of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
J Urol 181:972-9. 2009
..Pertinent literature regarding the potential use of testosterone therapy in men with prostate cancer is reviewed and synthesized...
- Commentary: Guideline for male testosterone therapy: a clinician's perspective
Abraham Morgentaler
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA
J Clin Endocrinol Metab 92:416-7. 2007
- Influence of baseline serum testosterone on changes in body composition in response to testosterone therapy
Stefania Di Sante
Men s Health Boston, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
J Sex Med 9:585-93. 2012
..The prognostic value of serum total testosterone (TT) prior to treatment has not been investigated...
- A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(®)) insertion
Andrew R McCullough
Albany Medical College, Albany, NY 12208, USA
J Sex Med 9:594-601. 2012
..Six academic institutions collaborated and combined their databases to more fully characterize serum testosterone levels after the pellet implantations...
- Rapidly shifting concepts regarding androgens and prostate cancer
Abraham Morgentaler
Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston USA
ScientificWorldJournal 9:685-90. 2009
..It will be interesting to see what changes will occur in this rapidly changing field over the next several years...
- Testosterone and prostate safety
Abraham Morgentaler
Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02445, USA
Front Horm Res 37:197-203. 2009
..Given that the population at risk for T deficiency overlaps with the population at risk for prostate cancer, it is strongly recommended that men undergoing T therapy undergo regular monitoring for prostate cancer...
- Testosterone and prostate cancer: an historical perspective on a modern myth
Abraham Morgentaler
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Eur Urol 50:935-9. 2006
..To review the historical origins and current evidence for the belief that testosterone (T) causes prostate cancer (pCA) growth...
- Y chromosome microdeletions and male infertility: who should be tested and why?
Luis Reyes-Vallejo
Division of Urology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA, USA
BJU Int 97:441-3. 2006
- The value of pituitary magnetic resonance imaging in men with hypogonadism
Ernani Luis Rhoden
Division of Urology, Beth Israel Deaconess Medical Center, Men's Health Boston, One Brookline Place, Suite 624, Brookline, MA 02445, USA
J Urol 170:795-8. 2003
..The decision to obtain MRI in these latter cases should be based on individual circumstances...
- The effect of aging on spermatogenesis and pregnancy outcomes
Stephen Lazarou
Division of Urology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA
Urol Clin North Am 35:331-9, xi. 2008
..This article reviews the available data on this topic, with an eye toward providing a basis for clinical counseling of the older man who wishes to have a child...
- The association of time of day and serum testosterone concentration in a large screening population
E David Crawford
Surgery and Radiation Oncology, Section of Urologic Oncology, UCHSC, Aurora, CO, USA
BJU Int 100:509-13. 2007
....
- The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men
Ernani Luis Rhoden
Department of Urology, Federal Foundation of Medical Sciences of Porto Alegre, Porto Alegre, Brazil
J Urol 179:1741-4. 2008
..We determined whether the ratio of serum testosterone to prostate specific antigen might provide diagnostic value regarding the risk of prostate cancer in a population of hypogonadal men undergoing prostate biopsy...
- New concepts regarding the relationship of testosterone and prostate cancer
Abraham Morgentaler
Future Oncol 3:123-6. 2007
- Penile rehabilitation should become the norm for radical prostatectomy patients
John P Mulhall
Sexual Medicine Program, Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Sex Med 4:538-43. 2007
..quot; At the suggestion of several SMSNA members, it was requested that this debate might be of interest to JSM readers in the form of a published controversy...
- Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship
Abraham Morgentaler
Eur Urol 52:623-5. 2007
- Re: Prostate cancer in men using testosterone supplementation. F. D. Gaylis, D. W. Lin, J. M. Ignatoff, C. L. Amling, R. F. Tutrone and D. J. Cosgrove
Abraham Morgentaler
J Urol 175:1572; author reply 1573-4. 2006
- Effects of chronic administration of dehydroepiandrosterone on serum testosterone levels and prostatic tissue in rats
Ernani Luis Rhoden
Postgraduate Course of Medical Sciences, Federal University of Rio Grande do Sul, Rua Jaragua 370 302, Bela Viste, 90450 140 Porto Alegre, RS, Brazil
J Urol 170:2101-3. 2003
..We evaluated the effects of chronic administration of dehydroepiandrosterone (DHEA) on serum total testosterone and DHEA sulfate (DHEAS), prostatic weight and histological features in the rat...
- Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy
Holly J Ramsawh
Department of Psychology, Boston University, Massachusetts 02215, USA
J Urol 174:1395-8. 2005
....
- Cultural biases and scientific squabbles: the challenges to acceptance of testosterone therapy as a mainstream medical treatment
Abraham Morgentaler
Aging Male 10:1-2. 2007
- Re: Masashi Yano, Takashi Imamoto, Hiroyoshi Suzuki et Al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur urol 2007;51:375-80
Abraham Morgentaler
Eur Urol 52:292; author reply 293-4. 2007
- Re: The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations
Abraham Morgentaler
J Urol 177:1954. 2007
